It’s All About Abecma As 2seventy Sells Off Pipeline To Regeneron In Restructuring

The cell therapy biotech will reduce its headcount from 280 to 65, with most of them – including two execs – going to Regeneron, which is paying just $5m up front to become a cell therapy player.